StockDuty ← Dashboard Jul 07, 2026 10:51 PM ET
SignalFDA/Bio

TVARDI THERAPEUTICS, INC. (TVRD) DISCUSSES PHASE 1 DATA ON TTI-109 STAT3 INHIBITOR HIGHLIGHTING PRODRUG DESIGN, TOLERABILITY AND TARGET ENGAGEMENT TRANSCRIPT - SEEKINGALPHA

Phase 1 data on TTI-109 STAT3 inhibitor provides catalyst with tolerability and target engagement.

What changed
Why it matters
Phase 1 data on TTI-109 STAT3 inhibitor provides catalyst with tolerability and target engagement.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →